Luca Massacesi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/39940/publications.pdf

Version: 2024-02-01

76326 88630 5,432 117 40 70 citations h-index g-index papers 120 120 120 6018 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents. Multiple Sclerosis and Related Disorders, 2022, 60, 103679.	2.0	3
2	Autologous haematopoietic stem cell transplantation versus lowâ€dose immunosuppression in secondary–progressive multiple sclerosis. European Journal of Neurology, 2022, 29, 1708-1718.	3.3	14
3	Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 820256.	2.4	6
4	Leptomeningeal Gadolinium Enhancement in Autoimmune GFAP Astrocytopathy. Neurology, 2022, 98, 720-722.	1.1	3
5	Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance. Neurological Sciences, 2022, , 1.	1.9	1
6	Prevalence of disability improvement as a potential outcome for multiple sclerosis trials. Multiple Sclerosis Journal, 2021, 27, 706-711.	3.0	6
7	Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 61-70.	3.0	16
8	Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102591.	2.0	8
9	Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology, 2021, 96, .	1.1	36
10	TCR repertoire diversity in Multiple Sclerosis: High-dimensional bioinformatics analysis of sequences from brain, cerebrospinal fluid and peripheral blood. EBioMedicine, 2021, 68, 103429.	6.1	18
11	Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs. Epilepsia, 2021, 62, 2159-2170.	5.1	31
12	Response: Brightening the crystal ball: A constructive reappraisal of the postwithdrawal seizure relapse prediction model. Epilepsia, 2021, 62, 3148-3149.	5.1	0
13	The "central vein sign―in patients with diagnostic "red flags―for multiple sclerosis: A prospective multicenter 3T study. Multiple Sclerosis Journal, 2020, 26, 421-432.	3.0	44
14	Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study. European Journal of Neurology, 2020, 27, 633-643.	3.3	29
15	Neurology and the COVID-19 emergency. Neurological Sciences, 2020, 41, 1343-1344.	1.9	8
16	Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. Journal of Neurology, 2020, 267, 3343-3353.	3.6	34
17	The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies. Frontiers in Immunology, 2020, 11, 559.	4.8	25
18	Association of celiac disease in patients with multiple sclerosis in Tuscany. Revista Espanola De Enfermedades Digestivas, 2020, 112, 474-476.	0.3	1

#	Article	IF	Citations
19	A case of recurrent progressive multifocal leukoencephalopathy after human stem cell transplant, with detection of John Cunningham virus and human herpesvirus 6 on cerebrospinal fluid, treated with Mirtazapine, Olanzapine and Foscarnet. Intractable and Rare Diseases Research, 2019, 8, 275-278.	0.9	1
20	Safety and efficacy of autologous hematopoietic stemâ€ell transplantation following natalizumab discontinuation in aggressive multiple sclerosis. European Journal of Neurology, 2019, 26, 624-630.	3.3	21
21	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	1.9	59
22	Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Annals of Neurology, 2018, 83, 283-294.	5. 3	160
23	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	10.2	238
24	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	3.0	101
25	Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis. JAMA Neurology, 2018, 75, 35.	9.0	65
26	Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study. Frontiers in Neurology, 2018, 9, 981.	2.4	64
27	Predictors of response to opicinumab in acute optic neuritis. Annals of Clinical and Translational Neurology, 2018, 5, 1154-1162.	3.7	19
28	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurology, 2017, 74, 459.	9.0	199
29	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 189-199.	10.2	210
30	Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). Neurological Sciences, 2017, 38, 231-236.	1.9	14
31	Magnetic resonance imaging of experimental autoimmune encephalomyelitis in the common marmoset. Journal of Neuroimmunology, 2017, 304, 86-92.	2.3	15
32	Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. Multiple Sclerosis and Related Disorders, 2017, 15, 24-26.	2.0	14
33	Proposal for a New Score-Based Approach To Improve Efficiency of Diagnostic Laboratory Workflow for Acute Bacterial Meningitis in Adults. Journal of Clinical Microbiology, 2016, 54, 1851-1854.	3.9	4
34	The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nature Reviews Neurology, 2016, 12, 714-722.	10.1	274
35	Operationalizing mild cognitive impairment criteria in small vessel disease: the VMCI-Tuscany Study. , 2016, 12, 407-418.		34
36	Efficacy for remyelination and safety of anti-lingo-1 monoclonal antibody (biib033) in acute optic neuritis: results from the renew study. Journal of the Neurological Sciences, 2015, 357, e14-e15.	0.6	1

#	Article	IF	CITATIONS
37	SWI enhances vein detection using gadolinium in multiple sclerosis. Acta Radiologica Open, 2015, 4, 204798161456093.	0.6	14
38	Autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurology, 2015, 84, 981-988.	1.1	201
39	Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e58.	6.0	6
40	Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy. Journal of NeuroVirology, 2015, 21, 666-670.	2.1	25
41	Fetal striatal grafting slows motor and cognitive decline of Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 974-981.	1.9	34
42	Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT. Annals of Clinical and Translational Neurology, 2014, 1, 650-658.	3.7	8
43	Development and Psychometric Properties of a Neuropsychological Battery for Mild Cognitive Impairment with Small Vessel Disease: The VMCI-Tuscany Study. Journal of Alzheimer's Disease, 2014, 43, 1313-1323.	2.6	29
44	The formation of inflammatory demyelinated lesions in cerebral white matter. Annals of Neurology, 2014, 76, 594-608.	5. 3	89
45	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurology, 2014, 14, 65.	1.8	47
46	Perivenular brain lesions in a primate multiple sclerosis model at 7-tesla magnetic resonance imaging. Multiple Sclerosis Journal, 2014, 20, 64-71.	3.0	25
47	Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial. PLoS ONE, 2014, 9, e113371.	2.5	37
48	Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. Clinical Neurology and Neurosurgery, 2013, 115, 1044-1048.	1.4	4
49	Carbon Nanotube Scaffolds Instruct Human Dendritic Cells: Modulating Immune Responses by Contacts at the Nanoscale. Nano Letters, 2013, 13, 6098-6105.	9.1	54
50	No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. Multiple Sclerosis Journal, 2012, 18, 1188-1192.	3.0	11
51	Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial. Trials, 2012, 13, 183.	1.6	19
52	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Multiple Sclerosis Journal, 2012, 18, 835-842.	3.0	115
53	Evolution of the blood–brain barrier in newly forming multiple sclerosis lesions. Annals of Neurology, 2011, 70, 22-29.	5.3	137
54	Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: A novel mechanism of AZA/6-MP. Journal of Neuroimmunology, 2010, 218, 28-35.	2.3	25

#	Article	IF	Citations
55	Inhibition of Immune Synapse by Altered Dendritic Cell Actin Distribution: A New Pathway of Mesenchymal Stem Cell Immune Regulation. Journal of Immunology, 2010, 185, 5102-5110.	0.8	78
56	Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Reactivation In Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Severe Multiple Sclerosis (MS) Blood, 2010, 116, 4537-4537.	1.4	0
57	Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. Journal of Neurology, 2009, 256, 1891-1898.	3.6	112
58	Clinical, Pathological, and Immunologic Aspects of the Multiple Sclerosis Model in Common Marmosets (<i>Callithrix jacchus</i>). Journal of Neuropathology and Experimental Neurology, 2009, 68, 341-355.	1.7	58
59	A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. Genes and Immunity, 2008, 9, 7-15.	4.1	20
60	Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment. Journal of Neuroimmunology, 2008, 199, 142-150.	2.3	71
61	Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Experimental Neurology, 2008, 211, 214-226.	4.1	49
62	A Key Role for Poly(ADP-Ribose) Polymerase-1 Activity during Human Dendritic Cell Maturation. Journal of Immunology, 2007, 179, 305-312.	0.8	57
63	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Multiple Sclerosis Journal, 2007, 13, 1068-1070.	3.0	53
64	Corrigendum to "Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans―[J. Neuroimmunol. 179 (2006) 108–116]. Journal of Neuroimmunology, 2007, 189, 175-176.	2.3	1
65	Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. Journal of Neuroimmunology, 2006, 179, 108-116.	2.3	29
66	Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Multiple Sclerosis Journal, 2006, 12, 814-823.	3.0	206
67	Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. Journal of Neuroimmunology, 2005, 168, 111-117.	2.3	7
68	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurological Sciences, 2005, 26, s200-s203.	1.9	17
69	Efficacy of Azathioprine on Multiple Sclerosis New Brain Lesions Evaluated Using Magnetic Resonance Imaging. Archives of Neurology, 2005, 62, 1843.	4.5	45
70	HLA–multiple sclerosis association in Continental Italy and correlation with disease prevalence in Europe. Journal of Neuroimmunology, 2004, 150, 178-185.	2.3	66
71	Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. Journal of Neuroimmunology, 2003, 143, 31-38.	2.3	12
72	A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. Journal of Neuroimmunology, 2003, 143, 97-100.	2.3	17

#	Article	IF	CITATIONS
73	Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. Human Immunology, 2003, 64, 274-284.	2.4	34
74	Compartmentalization of the immune response in the central nervous system and natural history of multiple sclerosis. Implications for therapy. Clinical Neurology and Neurosurgery, 2002, 104, 177-181.	1.4	14
75	Protein tyrosine phosphatase receptor-type C exon 4 gene mutation distribution in an Italian multiple sclerosis population. Neuroscience Letters, 2002, 328, 325-327.	2.1	33
76	Short-term dynamics of circulating T cell receptor V beta repertoire in relapsing–remitting MS. Journal of Neuroimmunology, 2002, 127, 149-159.	2.3	18
77	Multiple sclerosis and Type I diabetes. Diabetologia, 2002, 45, 1735-1736.	6. 3	9
78	Lipophilic modifications of peptide epitopes: T-cell response and susceptibility to peptidases. , 2002, , 697-699.		0
79	Recombinant MOG from baculovirus inhibits anti-hMOG(30-50) antibodies detected by the synthetic antigen [Asn31(Glc)]hMOG(30-50)., 2002,, 708-709.		0
80	Demyelination and axonal damage in a non-human primate model of multiple sclerosis. Journal of the Neurological Sciences, 2001, 184, 41-49.	0.6	74
81	Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. Neuroscience, 2001, 102, 687-695.	2.3	98
82	Palmitoyl Derivatives of GpMBP Epitopes: T-Cell Response and Peptidases Susceptibilityâ€. Journal of Medicinal Chemistry, 2001, 44, 3504-3510.	6.4	3
83	Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology, 2001, 57, 62-68.	1.1	156
84	Short-term evolution of autoreactive T cell repertoire in multiple sclerosis. Journal of Neuroscience Research, 2001, 66, 517-524.	2.9	13
85	Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis. Annals of Neurology, 2001, 50, 486-493.	5.3	58
86	A genome screen for multiple sclerosis in Italian families. Genes and Immunity, 2001, 2, 205-210.	4.1	70
87	IL-7-enhanced T-cell response to myelin proteins in multiple sclerosis. Journal of Neuroimmunology, 2001, 121, 111-119.	2.3	36
88	Oligoclonal T cell repertoire in cerebrospinal fluid of patients with inflammatory diseases of the nervous system. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 767-772.	1.9	8
89	Decrypting the spectrum of antigen-specific T-cell responses: the avidity repertoire of MBP-specific T-cells., 2000, 59, 86-93.		14
90	A new primate model for multiple sclerosis in the common marmoset. Trends in Immunology, 2000, 21, 290-297.	7.5	108

#	Article	IF	Citations
91	Use of technetium-99m hexamethylpropylene amine oxime SPET for the study of cerebral blood flow reactivity after acetazolamide infusion in patients with Beh§et's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 700-706.	6.4	8
92	Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. Neuroscience Letters, 2000, 296, 174-176.	2.1	37
93	A synthetic glycopeptide of human myelin oligodendrocyte glycoprotein to detect antibody responses in multiple sclerosis and other neurological diseases. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 167-172.	2.2	40
94	Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. European Journal of Human Genetics, 1999, 7, 377-385.	2.8	38
95	Title is missing!. International Journal of Peptide Research and Therapeutics, 1999, 6, 51-59.	0.1	1
96	Synthesis of lipopeptides of the immunodominant epitope hMBP(83–99) containing amide or C-C bond linked hydrophobic chains for the study of T cell response. International Journal of Peptide Research and Therapeutics, 1999, 6, 51-59.	0.1	1
97	HLA A2 allele is associated with age at onset of Alzheimer's disease. Annals of Neurology, 1999, 45, 397-400.	5. 3	29
98	Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus, 1999, 8, 11-19.	1.6	108
99	T-cell response to myelin basic protein and lipid-bound myelin basic protein in patients with multiple sclerosis and healthy donors. Journal of Neuroimmunology, 1998, 82, 96-100.	2.3	14
100	Detection of skewed T-cell receptor $V-\hat{l}^2$ gene usage in the peripheral blood of patients with multiple sclerosis. Journal of Neuroimmunology, 1998, 85, 22-32.	2.3	28
101	Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix) Tj ETQq1 1 0.78	43 <u>1</u> 4 rgBT	 Qyerlock 1
102	Histopathological Characterization of Magnetic Resonance Imaging-Detectable Brain White Matter Lesions in a Primate Model of Multiple Sclerosis. American Journal of Pathology, 1998, 153, 649-663.	3.8	145
103	Fas Gene Polymorphisms Are Not Associated With Systemic Lupus Erythematosus, Multiple Sclerosis And Hiv Infection. Disease Markers, 1998, 13, 221-225.	1.3	20
104	Immunosuppressive activity of 13-cis-retinoic acid in rats: aspects of pharmacokinetics and pharmacodynamics. Immunopharmacology, 1997, 37, 191-197.	2.0	10
105	Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for multiple sclerosis. Annals of Neurology, 1995, 37, 519-530.	5. 3	132
106	Transforming growth factor-?1 inhibits the proliferation of rat astrocytes induced by serum and growth factors. Journal of Neuroscience Research, 1995, 40, 127-133.	2.9	68
107	T-cell autoimmunity in multiple sclerosis. Trends in Immunology, 1995, 16, 259-261.	7.5	33
108	In healthy primates, circulating autoreactive T cells mediate autoimmune disease Journal of Clinical Investigation, 1994, 94, 1339-1345.	8.2	89

#	Article	IF	CITATIONS
109	Segregation of immunoglobulin heavy chain constant region genes in multiple sclerosis sibling pairs. Journal of Neuroimmunology, 1993, 42, 113-116.	2.3	15
110	Antibodies specific for the lipid-bound form of myelin basic protein during experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 1993, 44, 69-75.	2.3	20
111	Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid-bound form. Journal of the Neurological Sciences, 1993, 119, 91-98.	0.6	17
112	The role of prolactin in autoimmune demyelination: Suppression of experimental allergic encephalomyelitis by bromocriptine. Annals of Neurology, 1991, 29, 542-547.	5. 3	108
113	Lysosomal enzymes in experimental allergic encephalomyelitis: Time course and evidence of the source. Neurochemical Research, 1988, 13, 165-169.	3.3	5
114	Suppression of experimental allergic encephalomyelitis by retinoic acid. Journal of the Neurological Sciences, 1987, 80, 55-64.	0.6	45
115	DNA Changes in Spinal Cords of Rats with Experimental Allergic Encephalomyelitis. Journal of Neurochemistry, 1984, 43, 1635-1641.	3.9	12
116	Rhein and derivatives. In vitro stúdies on their capacity to inhibit certain proteases. Pharmacological Research Communications, 1982, 14, 103-112.	0.2	23
117	Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	2.4	1